BOLD
HEALTHCAREBoundless Bio, Inc. Common Stock
AI Insight
What's Moving BOLD Today?
No stock-specific AI insight has been generated for BOLD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.96$2.75
$2.60
Fundamentals
Market Cap$31M
P/E Ratio—
EPS$-2.49
Dividend Yield—
Dividend / Share—
ROE-50.2%
Profit Margin—
Debt / Equity—
Trading
Volume2.5M
Avg Volume (10D)—
Shares Outstanding22.5M
BOLD News
20 articles- Why Did BOLD, BLZE, QNT Stocks Surge To 52-Week Highs TodayStocktwits·Jun 24, 2026
- Sector Update: Healthcare Stocks Higher Late AfternoonYahoo Finance·Jun 23, 2026
- Sector Update: Healthcare Stocks Advance in Afternoon TradingYahoo Finance·Jun 23, 2026
- BOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company HistoryStocktwits·Jun 23, 2026
- Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private PlacementYahoo Finance·Jun 23, 2026
- [8-K] Boundless Bio, Inc. Reports Material EventStock Titan·Jun 17, 2026
- Boundless Bio Reports First Quarter 2026 Financial Results and Business HighlightsYahoo Finance·May 8, 2026
- Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual MeetingGlobeNewswire Inc.·Apr 17, 2026
- Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026Yahoo Finance·Mar 17, 2026
- Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsYahoo Finance·Mar 9, 2026
- Boundless Bio to Participate in the Leerink Global Healthcare ConferenceYahoo Finance·Mar 4, 2026
- Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's WhyYahoo Finance·Feb 13, 2026
- Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 5, 2026
- We're Keeping An Eye On Boundless Bio's (NASDAQ:BOLD) Cash Burn RateYahoo Finance·Jan 31, 2026
- Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash RunwayYahoo Finance·Jan 20, 2026
- Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare ConferenceYahoo Finance·Nov 24, 2025
- Boundless Bio Reports Third Quarter 2025 Financial Results and Business HighlightsYahoo Finance·Nov 5, 2025
- Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsYahoo Finance·Oct 13, 2025
- Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn SituationYahoo Finance·Aug 24, 2025
- Boundless Bio Reports Second Quarter 2025 Financial Results and Business HighlightsYahoo Finance·Aug 5, 2025
All 20 articles loaded
Price Data
Open$2.60
Previous Close$2.60
Day High$2.79
Day Low$2.58
52 Week High$2.75
52 Week Low$0.96
52-Week Range
$0.96$2.75
$2.60
Fundamentals
Market Cap$31M
P/E Ratio—
EPS$-2.49
Dividend Yield—
Dividend / Share—
ROE-50.2%
Profit Margin—
Debt / Equity—
Trading
Volume2.5M
Avg Volume (10D)—
Shares Outstanding22.5M
About Boundless Bio, Inc. Common Stock
Audentes Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious and life-threatening rare diseases caused by single gene defects. The company is headquartered in San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—